figloop.pages.dev

Peter fellner biography

    •

Peter Blaschke

Publications

The Legal 500: Country Comparative Guides 2025: Austira: Investing in January 2025

Augen auf! Die bloße Teilnahme an einer verbotenen Einlagenrückgewähr kann zur Haftung führen, GES 2021, 386 December 2023

Die Presse: Produktversprechen kritisch betrachten, co-author October 2023

Hauser/Blaschke, Trans-district mergers in the course of a squeeze-out, GesRZ 2008, 18 January 2008

Hauser/Blaschke, Exclusion of subscription rights at listed companies, ecolex 2006, 757ff and 839 ff October 2006

Education

  • Mag. iur., Universität Wien, 1997

Professional background

  • Attorney at Law with Fellner Wratzfeld & Partners since July 2021
  • Attorney at Law with a highly reputed Austrian law firm (2004 - June 2021)
  • Admitted to the Austrian bar in 2003
  • Associate with a highly reputed Austrian law firm (2000-2003)
    •

Dr Peter Fellner

  • Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America

  • Dr. Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America

  • Dr. L Stone Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America

  • Dr. L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America

  • Dr. Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America

  • Dr. R Sameh
    pediatrics
    King Abdul Aziz University
    United Arab Emirates

  • Dr. R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates

  • Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates

  • Dr. Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates

  • Dr. William
    pediatrics
    Maimonides Medical Center
    United States of America

      • •

    Vernalis plc

    UK-based pharmaceuticals business

    Vernalis plc was a UK-based pharmaceuticals business headquartered in Winnersh, with research in Cambridge, and with a Berwyn, PA, US-based commercial operation, Vernalis Therapeutics Inc., focusing on the sales and marketing of slow-release formulations of prescription cough and cold medicines. Tuzistra XR (codeine polistirex/ chlorpheniramine polistirex) was the first launched product which arose from this strategy,[1] however sales did not reach expectations.[2] As a result, the strategy was abandoned and the company was put up for sale.[3] Vernalis plc was listed on AIM until its acquisition by Ligand Holdings (UK) Ltd, a subsidiary of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) on 10 October 2018.[4]

    Vernalis plc (formerly known as British Biotech plc prior to 1 October 2003), arose from two company mergers.[5] The first merger, with the privately held Cambridge-based RiboTargets Holdings plc, was completed in April 2003, and brought a structure-based drug discovery capabili

    Copyright ©figloop.pages.dev 2025